Table 3.

Major candidate vaccines in phase II and III trials as of WHO data, 12 November 2020.

S. no.	Vaccine candidates, developers	Technology/platform	Current stage (participants)
1	BNT162 a1, b1, b2, c2, Pfizer/BioNTech	mRNA	Phase III cleared (38,000)
2	mRNA-1273, Moderna	Nanoparticle-based dispersion containing mRNA	Phase III cleared (30,000)
3	AZD1222, University of Oxford/AstraZeneca	Modified chimpanzee adenovirus (ChAdOx1)	Phase II-III (23,000)
4	COVAXIN, Bharat Biotech	Inactivated SARS-CoV-2	Phase III (30,000)
5	Unnamed, Sinopharm	Inactivated SARS-CoV-2 (Vero cells)	Phase III (15,000)
6	CoronaVac, Sinovac	Inactivated SARS-CoV-2	Phase III (10,490)